Aromatase inhibitors are either nonsteroidal (anastrozole and letrozole) or steroidal (exemestane), which led to questions surrounding possible differences in their potential protective effects seen in AD and dementia (eFigure 4 in the Supplement). The gene discussed is CYP19A1; the disease is dementia.